17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis
| Autor: | M Corinne Devlin, Douglas S Hepburn, Morrie M. Gelfand, Wilfred M Steinberg, Jacques E. Rioux |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
medicine.medical_specialty Estradiol vaginal tablet medicine.drug_class Administration Oral 030209 endocrinology & metabolism Premarin Vaginal Cream 03 medical and health sciences 0302 clinical medicine Vaginal Tablets Medicine Animals Humans Horses Prospective Studies Vaginitis Aged Gynecology Aged 80 and over 030219 obstetrics & reproductive medicine Estrogens Conjugated (USP) Estradiol business.industry Obstetrics and Gynecology Estrogens Middle Aged Patient Acceptance of Health Care medicine.disease Menopause Administration Intravaginal medicine.anatomical_structure Treatment Outcome Atrophic Vaginitis Estrogen Vagina Endometrial Hyperplasia Vaginal Creams Foams and Jellies Female Atrophy Follicle Stimulating Hormone business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Menopause (New York, N.Y.). 25(11) |
| ISSN: | 1530-0374 |
| Popis: | The efficacy and safety of 25-microg 17beta-estradiol vaginal tablets (Vagifem) were assessed and compared with 1.25-mg conjugated equine estrogen vaginal cream (Premarin Vaginal Cream) for the relief of menopausal-derived atrophic vaginitis, resulting from estrogen deficiency.In a multicenter, open-label, randomized, parallel-group study, 159 menopausal women were treated for 24 weeks with either vaginal tablets or vaginal cream. Efficacy was evaluated by relief of vaginal symptoms and concentrations of serum estradiol and follicle-stimulating hormone. Safety was monitored by the incidence of adverse events, evaluation of endometrial biopsies, and clinical laboratory results. Patients also assessed the acceptability of the study medications.Composite scores of vaginal symptoms (dryness, soreness, and irritation) demonstrated that both treatments provided equivalent relief of the symptoms of atrophic vaginitis. At weeks 2, 12, and 24, increases in serum estradiol concentrations and suppression of follicle-stimulating hormone were observed in significantly more patients who were using the vaginal cream than in those who were using the vaginal tablets (p0.001). Fewer patients who were using the vaginal tablets experienced endometrial proliferation or hyperplasia compared with patients who were using the vaginal cream. Significantly more patients who were using the vaginal tablets rated their medication favorably than did patients who were using the vaginal cream (por = 0.001). Patients who were receiving the vaginal tablets also had a lower incidence of patient withdrawal (10% versus 32%).Treatment regimens with 25-microg 17beta-estradiol vaginal tablets and with 1.25-mg conjugated equine estrogen vaginal cream were equivalent in relieving symptoms of atrophic vaginitis. The vaginal tablets demonstrated a localized effect without appreciable systemic estradiol increases or estrogenic side effects. Vaginal tablet therapy resulted in greater patient acceptance and lower withdrawal rates compared with vaginal cream therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|